regulatory and quality system professionals | 919.313.3960
Regulating Medical Devices Shapes Industry for the Better

Regulating Medical Devices Shapes Industry for the Better

This article originally appeared in Business Worldwide magazine. It’s fashionable to be anti-regulation in business today. But sometimes regulation is central to how a sector operates. We talk to Rita King, CEO of MethodSense and Russ King, President of MethodSense about why regulation of medical device, biotech and pharma companies is so critical. Most devices and innovations need to go through a complex system of regulatory approval. In order to obtain market entry, some argue that regulatory agencies like the US-based Food and Drug Administration (FDA) are too zealous, preventing or delaying life-saving innovations from entering the market. Richard Williams, an affiliated scholar at the Mercatus Center at George Mason University, cites an example where three medical devices submitted for approval took nine years to process. He argues that it costs on average $24 million to manage FDA requirements. “A mid-1970s law,” he argues, “requires virtually every medical device—and improvements to existing devices—to endure a slow, expensive, uncertain approval process, ill-suited to 21st-century technology. The Food and Drug Administration (FDA), which grants such approval, has an ageing structure and culture that adds extra layers of discouragement to would-be innovators.” But what are the benefits of regulation, and how can pharma and tech companies manage the process of compliance more smoothly? MethodSense is a company that exists to assist companies with FDA and other regulatory agencies to obtain market entry for their medical device products. We talked to Rita King, CEO of MethodSense, and Russ King, President of MethodSense, about what they do and why regulation matters. What kinds of services do you provide as a company? “MethodSense’s consulting service approach is a...
MethodSense Inc. CEO WiMethodSense Inc. CEO Wins Global Leadershipns Global Leadership Award with Business Worldwide Magazine

MethodSense Inc. CEO WiMethodSense Inc. CEO Wins Global Leadershipns Global Leadership Award with Business Worldwide Magazine

We are pleased to announce that CEO Rita King was named “Healthcare CEO of the Year – USA” by Business Worldwide Magazine. Full text of the press release is below… LONDON, October 4, 2018 /PRNewswire. The chief executive of life science consulting firm MethodSense has gained global recognition for outstanding leadership in the Business Worldwide Magazine (BWM) 2018 CEO Awards. Rita King was named ‘Healthcare CEO of the Year –USA‘ for her sterling work at the helm of the North Carolina-based company. The 2018 Business Worldwide CEO Awards identify and honour the Most Respected C-level executives across the globe from a variety of different sectors. Unlike many business awards that focus on the overall achievements of specific companies, the approach here is to focus instead on the personalities at their helm, inspiring others to achieve similar successes. MethodSense offers life science and medical device regulatory compliance; guiding medical device, biotech and pharmaceutical companies and supporting them through the commercialisation process and beyond. It’s an industry that’s notoriously difficult to navigate, with many submissions taking years to be approved by regulatory bodies like the Food and Drug Administration (FDA). Through their comprehensive methods, MethodSense assists in all aspects of regulation, compliance and commercialization efforts. MethodSense seeks to simplify the process of bringing, or keeping, a medical device or combination product to market, enabling them to commercialize their innovations. In a career spanning more than 26 years, Rita King has garnered an impressive international reputation as a regulatory expert. She has participated in numerous national and international committees and is a founding member of the Underwriters Laboratories team. A highly sought-after speaker, her thoughts on...
Artificial Intelligence and the FDA

Artificial Intelligence and the FDA

The tech world is exploding around the realities and possibilities of Artificial Intelligence (AI). Artificial Intelligence makes it possible for machines to learn from experience, adjust to new inputs and perform human-like tasks reflecting what we normally think requires natural intelligence.  There are currently relatively few FDA cleared products that use Artificial intelligence on the market.  But the use of AI in the development of medical devices is accelerating dramatically because AI holds a great deal of promise for solving health problems. But as a relatively new tool for medical device developers and with rising interest in applying AI to solving health problems, what is the FDA concerned about? FDA and Artificial Intelligence In general, the FDA is seeking to ensure the safety and efficacy of new devices using AI while doing so in a way that doesn’t hamper innovation. This balancing act is nothing new for the FDA; but how the FDA is managing safety and efficacy for medical devices incorporating AI is undergoing refinement. The FDA has its traditional concerns about AI as a software tool: validation, software development lifecycle management and documentation, the need for well controlled study designs, etc. But AI also presents some new, interesting challenges: AI programs often depend on real-world benchmark data as original inputs. The real world is notorious for its variability, so how do you justify the benchmark data chosen?How do you insure that the benchmark data chosen supports the intended use of the device?If you need to re-train your AI algorithm with new real-world data, what does that mean for the status of the device as a cleared medical device?There are different kinds of...
Advocate v. Adversary: why your perception of the FDA can affect your submission

Advocate v. Adversary: why your perception of the FDA can affect your submission

Ensuring a FDA 510(k) submission is done properly is critical to getting your medical device into the market and monetizing your development. And the speed with which you complete your submission can drive significant business value. Timeliness is key, as is completeness and accuracy. This is the business value we seek to bring to our clients. For one client we were able to get the submission done far ahead of schedule and in the face of the FDA doubting the ability to achieve product clearance.  We believed we could be successful and ask the FDA to work with us on the success path we could see in front of us.  The FDA agreed and because we believe in building appropriate relationships with FDA reviewers all parties experienced success. While at the FDA for another project, we requested a brief discussion with the client’s reviewer while visiting the FDA on another matter for the simple purpose of enabling understanding.  After a very brief discussion with the reviewer, we were able to better understand how to meet the reviewer’s expectations.   The reviewer also better understood the client’s perspective and goals.  Our brief “out of process” meeting created the foundations for better communication which further accelerated the submission review and 510(k) clearance. A collaborative and comprehensive approach to FDA 510(k) submission If you look at the FDA as a roadblock or adversary, your mindset will influence the way your approach those interactions. MethodSense believes a collaborative and comprehensive approach to submissions delivers the best business value. A well-done 510(k), combined with confidence and positive view can greatly simplify the process.  And MethodSense...
FDA Announces FY 2018 MDUFA Fees

FDA Announces FY 2018 MDUFA Fees

MDUFA Fee Increases and FDA Small Business Certification The FDA has recently announced the fee rates and procedures for medical device user fees for fiscal year 2018 in the Federal Register. Under the FD&C Act, as amended by the Medical Device User Fee Amendments of 2017 (MDUFA IV), FDA is authorized to collect user fees for certain medical device applications, submissions, reporting on class III devices and fees for establishments subject to registration. These fees are in effect from October 1, 2017 through September 30, 2018. 2018 MDUFA Fees FDA user fees have increased across all categories. This increase will substantially impact larger companies. Most FDA user fees increased 33%; however the standard application fee for a 510(k) submission rose 125% to $10,566. The increase in fees is a result of inflation adjustment plus any additional increase FDA feels is necessary to reach the inflation adjusted total revenue amount the agency has identified for the year. Application Type 2018 Standard Fees 2018 Small Business Fees 510(k) premarket notification submission $10,566 (+125%) $2,642 (+13%) 513(g) request for classification information $4,195 (+33%) $2,098 (+33%) Premarket application (PMA) $310,764 (+33%) $77, 691 (+33%) De novo classification request $93,229 (new) $23,307 (new) Annual fee for periodic reporting on a class III device $10,877 (+33%) $2,719 (+33%) Annual establishment registration $4,624 (+37%) $4,624 (+37%) Qualifying for Small Business User Fees At the same time that the FDA announced their 2018 fees, they also updated their guidance FY 2018 Medical Device User Fee Small Business Qualification and Certification. A business that is qualified as a “small business” is eligible for reduced user fees. A small...